Alembic Pharmaceuticals has received USFDA approval for Clonazepam orally disintegrating tablets which are used for treatment of seizures, adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures .
The approved drug is therapeutically equivalent to Klonopin produced by Hoffmann-La Roche, Inc. The drug will be produced in strengths of 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg. According to market estimates, Clonazepam orally disintegrating tablets USP has an estimated market size of USD 20 million for 12 months ending December 2018.
Company Profile : Alembic Pharmaceuticals Ltd